Now showing items 1-1 of 1

    • Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. 

      Lingappa, JR; Baeten JM, Hughes JP, Thomas KK Wald A,; Mujugira A, Bukusi EA, Cohen CR Mugo N,; Katabira E, Kiarie J, Farquhar C Ronald A,; Stewart GJ, Essex M, Were E Makhema J,; Fife KH, Gray GE, McIntyre JA de Bruyn G,; Manongi R, Coetzee D, Allen S, Kapiga S,; Inambao M, Karita E, Kanweka W Kayitenkore K,; Delany S, Vwalika B, Magaret AS Rees H,; Wang RS, Barnes L, Ridzon R Kidoguchi L; Corey L, Celum C (Department of Global Health, Seattle, WA, USA, 2010)
      BACKGROUND: Most people infected with HIV-1 are dually infected with herpes simplex virus type 2. Daily suppression of this herpes virus reduces plasma HIV-1 concentrations, but whether it delays HIV-1 disease progression ...